More NewsRead More
Michael Grey Joins Mirati Therapeutics Board of Directors
November 06, 2014
Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
September 10, 2014
Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
September 04, 2014
Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma
August 11, 2014
Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
August 08, 2014
Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome
June 17, 2014
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here